- Home
- KFS vs GNLX Comparison
KFS vs GNLX Comparison
Compare KFS & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KFS
- GNLX
- Stock Information
- Founded
- KFS 1989
- GNLX 2001
- Country
- KFS United States
- GNLX United States
- Employees
- KFS N/A
- GNLX N/A
- Industry
- KFS Property-Casualty Insurers
- GNLX Biotechnology: Pharmaceutical Preparations
- Sector
- KFS Finance
- GNLX Health Care
- Exchange
- KFS Nasdaq
- GNLX Nasdaq
- Market Cap
- KFS 220.3M
- GNLX 184.4M
- IPO Year
- KFS 1996
- GNLX 2023
- Fundamental
- Price
- KFS $8.09
- GNLX $2.63
- Analyst Decision
- KFS
- GNLX Strong Buy
- Analyst Count
- KFS 0
- GNLX 4
- Target Price
- KFS N/A
- GNLX $18.25
- AVG Volume (30 Days)
- KFS 109.1K
- GNLX 233.3K
- Earning Date
- KFS 05-07-2025
- GNLX 05-08-2025
- Dividend Yield
- KFS N/A
- GNLX N/A
- EPS Growth
- KFS N/A
- GNLX N/A
- EPS
- KFS N/A
- GNLX N/A
- Revenue
- KFS $112,710,000.00
- GNLX $8,000.00
- Revenue This Year
- KFS N/A
- GNLX N/A
- Revenue Next Year
- KFS N/A
- GNLX N/A
- P/E Ratio
- KFS N/A
- GNLX N/A
- Revenue Growth
- KFS 3.29
- GNLX N/A
- 52 Week Low
- KFS $7.06
- GNLX $1.60
- 52 Week High
- KFS $9.58
- GNLX $5.89
- Technical
- Relative Strength Index (RSI)
- KFS 57.21
- GNLX 42.31
- Support Level
- KFS $7.28
- GNLX $2.30
- Resistance Level
- KFS $8.14
- GNLX $2.68
- Average True Range (ATR)
- KFS 0.33
- GNLX 0.26
- MACD
- KFS 0.03
- GNLX 0.05
- Stochastic Oscillator
- KFS 60.45
- GNLX 55.49
About KFS Kingsway Financial Services Inc. (DE)
Kingsway Financial Services Inc through subsidiaries operates in the extended warranty and business services industries in the United States. The company operates through segments namely, Extended Warranty and Kingsway Search Xcelerator. The Extended Warranty segment provides after-market vehicle protection services distributed by credit unions. The firm generates maximum revenue from the Extended Warranty segment in the form of Service fee and commission income.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec) and others.